Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis

J Cyst Fibros. 2020 May 26;S1569-1993(20)30130-2. doi: 10.1016/j.jcf.2020.04.017. Online ahead of print.


Elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the Food and Drug Administration in October 2019 for treatment of cystic fibrosis (CF) in patients 12 years and older with at least one F508del mutation in the CFTR protein. There were no documented reports of testicular pain during clinical trials. In this case series, we discuss 7 males between 17 and 39 years of age who reported testicular pain or discomfort within the first two weeks of starting therapy. The precise mechanism of this side effect is unknown, but it may be related to restoration of CFTR function in the male reproductive tract. All patients experienced resolution of this side effect within a week after onset, regardless of the management, except for one. Further research is needed to determine short- and long-term impact of this drug on male fertility. Until more data is available, the authors recommend counseling patients on contraceptive options.

Keywords: Adverse reactions; Congenital bilateral absence of the vas deferens; Cystic fibrosis; Drug-related side effects; Elexacaftor; Infertility; Male.

Publication types

  • Case Reports